• Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Logo
  • COVID-19 Resource Center
  • Categories
    • Feature
    • Cardiology trends
    • Cardiology research news
    • Conference coverage
    • Consensus reports & Position papers
    • Resources for Cardiology Professionals
    • COVID-19 Resource Center
  • Videos
  • Cardiology Best Practices

Cardiology Update

The latest trends and advancements made in cardiology research.

Role of iron deficiency in chronic heart failure

January 30, 2019

Reading Time: 2 minutes

Muscle function is highly dependent on oxidative phosphorylation as a source of energy. Interestingly, iron deficiency has been shown to have severe effects on muscle function due to its effect on hematopoiesis, as well as muscle bioenergetics. It is this link that prompted Melenovsky et al. to explore the role of iron deficiency in heart failure (HF). With reports showing that approximately half of HF patients suffer from iron deficiency (ID), iron supplementation could be an important point of intervention beyond the correction of hemoglobin levels.

Melenovsky et al. conducted their study on a group of 44 chronic HF and 25 healthy control patients. They used magnetic resonance spectroscopy (31P MRS) method to measure parameters related to muscle function (maximal isometric strength), energy production (concentration of phosphocreatine, ATP and inorganic phosphate), and acidosis. Presented results support the hypothesis that ID correlates with the severity of the HF symptoms, as measured by the skeletal muscle myopathy and greater phosphocreatine change during exercise (PCr drop/work: 5.6 W-1 in controls compared to 9.1W-1 in HF group, p = 0.03). This change was even more pronounced in the HF-ID group (9.4 W-1, p = 0.27 compared to HF group without ID). Furthermore, in HF-ID patients exercise induced change in PCr correlated with muscle acidosis (r = 0.74, p < 0.0001) which was not the case in HF patients without ID nor in control healthy subjects (r = 0.03, p = 0.94). This correlation is likely a result of a shift from oxidative phosphorylation towards anaerobic glycolysis, and it underlies symptoms like fatigue and impaired muscle performance.

In the final experiment, authors tested if iron supplementation by intravenous ferric carboxymaltose administration was sufficient to restore normal muscle function within one month. While such treatment restored the hemoglobin levels, it did not result in a significant improvement of muscle performance. Together, this suggests that iron interventions may require longer durations to become fully effective. Overall, due to the small patient group and short observation time limiting the final conclusion of the study authors postulate that iron should remain in the scope of future, systemic, and prolonged studies.

CLINICAL IMPACT
Heart failure patients commonly show iron deficiency and are more symptomatic (lower peak muscle strength and greater acidification of muscle during exercise).
This is supportive of metabolic shift towards anaerobic glycolysis.
Targeting iron deficiency in HF patients may improve exercise capacity, beyond the correction of hemoglobin levels.

Original article: Circ Heart Fail. 2018 Sep;11(9):e004800. 

Author:  Gabriela Plucinska


Check Out Related Articles

  • Treating iron deficiency in chronic heart failure patientsTreating iron deficiency in chronic heart failure patients
  • COVID-19 and the HeartCOVID-19 and the Heart
  • COVID-19 and Cardiovascular ComplicationsCOVID-19 and Cardiovascular Complications

Primary Sidebar

Cardiology News Highlights

  • Facebook
  • Instagram
  • LinkedIn
  • Twitter

Most featured

Statin therapy: clinical benefits and potential risks

Statin therapies prevent both primary and secondary cardiovascular disease.However, long term safety … Continue Reading about Statin therapy: clinical benefits and potential risks

Cardiology Conferences 2021

Top Cardiology Conferences 2021

With the COVID-19 worldwide pandemic, conferences and congresses planned for 2020 converted to … Continue Reading about Top Cardiology Conferences 2021

N of 1 Trial - Statin side effects

SAMSON Trial: Role of nocebo effect in statin-associated muscle symptoms

The phenomenon of non-adherence to statin therapy is well known. Reasons for discontinuation include … Continue Reading about SAMSON Trial: Role of nocebo effect in statin-associated muscle symptoms

Browse by topic

Cardiac surgery Electrophysiology General cardiology Heart failure Imaging Interventional cardiology

Footer

Cardiology Update

Providing up-to-date developments in the field of cardiology in a clear and concise manner. All articles are written by professional medical journalists and subsequently reviewed by our editorial board. Cardiology Update provides breaking news, that matter to healthcare professionals in the field of cardiology. Subscribe for free to keep up with cardiology news updated regularly.

Learn More About Us

Contact Us

Recent

  • Top Cardiology Conferences 2021
  • SAMSON Trial: Role of nocebo effect in statin-associated muscle symptoms
  • Top 10 Highlights of AHA 2020 Congress
  • Thromboembolism in COVID-19 patients despite thromboprophylaxis
  • Top 10 highlights of TCT 2020 Congress

Search

Browse by topic

Cardiac surgery Electrophysiology General cardiology Heart failure Imaging Interventional cardiology

Terms & Conditions | Privacy | Disclaimer
© Clinicalinx B.V. All rights reserved. Postbus 2278, 1000 CG Amsterdam

We use cookies to provide the services and features offered on our website, and to improve our user experience. Learn more Ok
Privacy & Cookies Policy
Necessary Always Enabled